Drug Profile
CC 31244
Alternative Names: CC-31244; CDI 31244Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Emory University
- Developer Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 07 Dec 2022 Phase II development in Hepatitis C (Combination therapy) is ongoing in USA (PO) (Cocrystal Pharma pipeline, December 2022)
- 14 May 2020 CC 31244 is available for licensing as of 14 May 2020. https://www.cocrystalpharma.com/about/partnerships-licensing
- 14 May 2020 Cocrystal Pharma and Humanity & Health Research Centre withdrew phase II trial in Hepatitis C (combination therapy) in Hong Kong (PO) (NCT03794258)